- Home
- ACAD vs SFBS Comparison
ACAD vs SFBS Comparison
Compare ACAD & SFBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SFBS
- Stock Information
- Founded
- ACAD 1993
- SFBS 2005
- Country
- ACAD United States
- SFBS United States
- Employees
- ACAD N/A
- SFBS N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SFBS Major Banks
- Sector
- ACAD Health Care
- SFBS Finance
- Exchange
- ACAD Nasdaq
- SFBS Nasdaq
- Market Cap
- ACAD 4.3B
- SFBS 4.6B
- IPO Year
- ACAD 2004
- SFBS 2014
- Fundamental
- Price
- ACAD $24.67
- SFBS $83.93
- Analyst Decision
- ACAD Buy
- SFBS Hold
- Analyst Count
- ACAD 21
- SFBS 1
- Target Price
- ACAD $29.30
- SFBS $90.00
- AVG Volume (30 Days)
- ACAD 1.8M
- SFBS 209.6K
- Earning Date
- ACAD 11-05-2025
- SFBS 10-20-2025
- Dividend Yield
- ACAD N/A
- SFBS 1.60%
- EPS Growth
- ACAD 615.00
- SFBS 26.23
- EPS
- ACAD 1.33
- SFBS 4.57
- Revenue
- ACAD $1,018,885,000.00
- SFBS $488,391,000.00
- Revenue This Year
- ACAD $14.01
- SFBS $25.86
- Revenue Next Year
- ACAD $11.72
- SFBS $14.42
- P/E Ratio
- ACAD $18.55
- SFBS $18.32
- Revenue Growth
- ACAD 14.41
- SFBS 18.16
- 52 Week Low
- ACAD $13.40
- SFBS $66.48
- 52 Week High
- ACAD $26.65
- SFBS $101.37
- Technical
- Relative Strength Index (RSI)
- ACAD 49.69
- SFBS 47.34
- Support Level
- ACAD $23.34
- SFBS $83.31
- Resistance Level
- ACAD $25.90
- SFBS $89.62
- Average True Range (ATR)
- ACAD 0.78
- SFBS 1.71
- MACD
- ACAD -0.28
- SFBS -0.66
- Stochastic Oscillator
- ACAD 40.18
- SFBS 16.32
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SFBS ServisFirst Bancshares Inc.
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary, ServisFirst Bank. Through the bank, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.